The European Commission (EU) has secured 250 million doses of COVID-19 vaccine from Spanish pharmaceutical company, HIPRA Human Health.
The joint procurement deal will see 14 countries having access to the vaccine.
The commission signed the contract in preparation for autumn and winter, EU Health Commissioner Stella Kyriakides said in a statement on Tuesday.
Ebenezer Obey: Doctors told me my son has less than 6 months to live
The commission said participating countries in the joint purchasing agreement with HIPRA could donate the vaccines to other less-wealthy countries if they wish to do so.
The vaccine, currently under review at the European Medicines Agency (EMA), is designed as a booster dose for persons older than 16 that already had been vaccinated against COVID-19.
According to the commission, once the new vaccine has received EMA approval, EU countries can purchase vaccines through the agreed framework with HIPRA.
Stored at temperatures of between two and eight degrees Celsius, the commission said this refrigerated temperature facilitates distribution in Europe and around the rest of the world.
So far the EU had secured the option to buy 4.2 billion COVID-19 doses under the bloc’s procurement strategy, among them vaccines from AstraZeneca, Moderna, and BioNtech-Pfizer, the commission said.
- 119 inmates escape as rainstorm destroys Niger prison - April 25, 2024
- Judge’s daughter seeks share of late father’s property - April 25, 2024
- MTN, Glo, Airtel seek upward review of service prices - April 25, 2024
